20.01.2015 • News

German Chemical Industry Wants to Preserve TTIP Clause

Germany's chemical producers have spoken up again on the Transatlantic Trade and Investment Pact (TTIP), which is being heatedly debated across Europe.

Following a discussion in the German Bundestag on the proposed Investor-to-State Dispute Settlement (ISDS) clause under which companies can challenge the laws of other countries they consider a hindrance to free trade, the industry association Verband der Chemischen Industrie (VCI), which in general favors the pact, said this would be "totally wrong."

While VCI general manager Utz Tillmann said the association also sees a need for reform of ISDS and suggested that "one approach might be to set up an international commercial court for appeals," he stressed that - from the industry's perspective, excluding the topic "would be the proverbial head-in-the-sand strategy."

As the debate continues to rage, even EU officials now appear to conclude that TTIP possibly could fail. "All EU member states must ratify the treaty, and at the moment I don't see a secure majority in favor," health commissioner Vytemis Andriukaitis told a German newspaper.

On the sidelines of the recent International Green Week agriculture show in Berlin, an estimated 25,000 people demonstrated against TTIP, genetically manipulated crops and factory farming.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read